Bristol-Myers Squibb Compnay

Viiv Healthcare UK (No.5) Limited

Viiv Healthcare UK (No. 4) Limited

Viiv Healthcare UK Limited

Alicia Regueiro-Ren

Nicholas A Meanwell

Jacob Swidorski

Sing-Yuen Sit

Jie Chen

Zheng Liu

Yan Chen

John F Kadow

Ny Sin

Tao Wang

Zhongxing Zhang

Zhiwei Yin

Richard A Hartz

Yasutsugu Ueda

Brian Lee Venables

Manoranjan Panda

David J Carini

Prasada Rao Jalagam

David S Yoon

Li Xu

Lawrence G Hamann

Chunjian Liu

Qiufen May Xue

Satheesh Kesavan Nair

John D Matiskella

Soong-Hoon Kim

Gregory D Vite

Bruce A Ellsworth

Robert Michael Borzilleri

Thomas W Hudyma

Pratik Devasthale

Susheel Jethanand Nara

Xiaofan Zheng

Ying Han

Brett R Beno

Wei Wang

Barry L Johnson

Jianxin Feng

Ira B Dicker

Beata Nowicka-Sans

Piyasena Hewawasam

James Aaron Balog

B Narasimhulu Naidu

Kap-Sun Yeung

John A Bender

Natesan Murugesan

Joanne J Bronson

Shoshana L Posy

Robert G Gentles

Ramakanth Sarabu

Jason T Goodrich

Katharine A Grant-Young

Scott W Martin

Gang Wu

Timothy P Connolly

Andrew P Degnan

Margaret E Sorenson

Yong Tu

Oak K Kim

Yunhui Zhang

Carl P Bergstrom

Wenying Li

Animesh Goswami

Dane M Springer

Zhiwei Guo

Michael Mandler

Thomas P Tully

Nicolas A Meanwell

The present invention relates to 1H-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis

The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).

Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis

The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Galectin-3 inhibitors

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of galectin-3

The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Small molecule inhibitors of Galectin-3

The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.

Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. 

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

C-3 and C-17 modified triterpenoids as HIV-1 inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, azadecaline derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: These compounds are useful for the treatment of HIV and AIDS.

Azadecalin derivatives as inhibitors of human immunodeficiency virus replication

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:  These compounds are useful for the treatment of HIV and AIDS.

Growing community of inventors

Middletown, CT, United States of America

Alicia Regueiro-Ren